Vtv Therapeutics Stock Analysis
| VTVT Stock | USD 22.33 0.48 2.10% |
vTv Therapeutics is undervalued with Real Value of 26.3 and Target Price of 35.5. The main objective of VTv Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what vTv Therapeutics is worth, separate from its market price. There are two main types of VTv Therapeutics' stock analysis: fundamental analysis and technical analysis.
The VTv Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. VTv Therapeutics is usually not traded on Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday. VTv Stock trading window is adjusted to America/New York timezone.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in vTv Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. VTv Stock Analysis Notes
About 36.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 2.92. vTv Therapeutics had not issued any dividends in recent years. The entity had 1:40 split on the 21st of November 2023. vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews Forbes Incorporated. Vtv Theraptcs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. For more information please call Paul MSc at 336 841 0300 or visit https://vtvtherapeutics.com.vTv Therapeutics Investment Alerts
| vTv Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 1.02 M. Net Loss for the year was (22.7 M) with loss before overhead, payroll, taxes, and interest of (11.78 M). | |
| vTv Therapeutics currently holds about 17.95 M in cash with (25.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| vTv Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 36.0% of the company outstanding shares are owned by insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Akkaraju Srinivas of 106000 shares of VTv Therapeutics at 15.265 subject to Rule 16b-3 |
vTv Therapeutics Upcoming and Recent Events
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
VTv Largest EPS Surprises
Earnings surprises can significantly impact VTv Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-10 | 2022-09-30 | -0.04 | -0.05 | -0.01 | 25 | ||
2020-05-07 | 2020-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2022-05-12 | 2022-03-31 | -0.08 | -0.1 | -0.02 | 25 |
VTv Therapeutics Environmental, Social, and Governance (ESG) Scores
VTv Therapeutics' ESG score is a quantitative measure that evaluates VTv Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of VTv Therapeutics' operations that may have significant financial implications and affect VTv Therapeutics' stock price as well as guide investors towards more socially responsible investments.
VTv Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2025-06-30 | 170 | Activest Wealth Management | 2025-06-30 | 50.0 | Corecap Advisors, Llc | 2025-06-30 | 45.0 | Parallel Advisors, Llc | 2025-06-30 | 38.0 | Sunbelt Securities | 2025-06-30 | 15.0 | Bank Of America Corp | 2025-06-30 | 12.0 | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 9.0 | Sbi Securities Co Ltd | 2025-06-30 | 2.0 | Strategic Wealth Partners | 2025-06-30 | 1.0 | Samsara Biocapital, Llc | 2025-06-30 | 206.8 K | Fmr Inc | 2025-06-30 | 178.2 K |
VTv Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 58.44 M.VTv Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.73) | (0.77) | |
| Return On Assets | (0.48) | (0.51) | |
| Return On Equity | (1.51) | (1.44) |
Management Efficiency
vTv Therapeutics has return on total asset (ROA) of (0.4393) % which means that it has lost $0.4393 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0904) %, meaning that it created substantial loss on money invested by shareholders. VTv Therapeutics' management efficiency ratios could be used to measure how well VTv Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.51 in 2025. Return On Capital Employed is likely to drop to -0.77 in 2025. Non Current Liabilities Other is likely to gain to about 23.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 4.9 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.48 | 2.60 | |
| Tangible Book Value Per Share | 2.48 | 2.60 | |
| Enterprise Value Over EBITDA | (1.92) | (2.01) | |
| Price Book Value Ratio | 6.53 | 6.86 | |
| Enterprise Value Multiple | (1.92) | (2.01) | |
| Price Fair Value | 6.53 | 6.86 | |
| Enterprise Value | 43.1 M | 61.3 M |
The leadership approach at VTv Therapeutics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Technical Drivers
As of the 28th of September, VTv Therapeutics has the Risk Adjusted Performance of 0.099, coefficient of variation of 691.83, and Semi Deviation of 2.62. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of vTv Therapeutics, as well as the relationship between them.vTv Therapeutics Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triangular Moving Average shows VTv Therapeutics double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
vTv Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific VTv Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on VTv Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases VTv Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
VTv Therapeutics Outstanding Bonds
VTv Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. vTv Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most VTv bonds can be classified according to their maturity, which is the date when vTv Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Viking Cruises Ltd Corp BondUS91832VAA26 | View | |
| US91835HAA05 Corp BondUS91835HAA05 | View |
VTv Therapeutics Predictive Daily Indicators
VTv Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of VTv Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 22.33 | |||
| Day Typical Price | 22.33 | |||
| Price Action Indicator | (0.24) | |||
| Period Momentum Indicator | (0.48) |
VTv Therapeutics Corporate Filings
F4 | 25th of September 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 10th of September 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 8th of September 2025 Other Reports | ViewVerify | |
F4 | 5th of September 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of September 2025 Other Reports | ViewVerify | |
8K | 2nd of September 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 12th of August 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 12th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
VTv Therapeutics Forecast Models
VTv Therapeutics' time-series forecasting models are one of many VTv Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary VTv Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About VTv Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how VTv Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling VTv shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as VTv Therapeutics. By using and applying VTv Stock analysis, traders can create a robust methodology for identifying VTv entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (20.00) | (21.00) | |
| Operating Profit Margin | (21.40) | (22.47) | |
| Net Loss | (16.34) | (17.15) | |
| Gross Profit Margin | 0.82 | 0.86 |
Current VTv Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. VTv analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. VTv analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 35.5 | Strong Buy | 2 | Odds |
Most VTv analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand VTv stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of vTv Therapeutics, talking to its executives and customers, or listening to VTv conference calls.
VTv Stock Analysis Indicators
vTv Therapeutics stock analysis indicators help investors evaluate how VTv Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading VTv Therapeutics shares will generate the highest return on investment. By understating and applying VTv Therapeutics stock analysis, traders can identify VTv Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 9.4 M | |
| Common Stock Shares Outstanding | 5.8 M | |
| Total Stockholder Equity | 12.2 M | |
| Tax Provision | 100 K | |
| Property Plant And Equipment Net | 153 K | |
| Cash And Short Term Investments | 36.7 M | |
| Cash | 36.7 M | |
| Accounts Payable | 939 K | |
| Net Debt | -36.6 M | |
| 50 Day M A | 17.3532 | |
| Total Current Liabilities | 5.2 M | |
| Other Operating Expenses | 25.2 M | |
| Non Current Assets Total | 153 K | |
| Stock Based Compensation | 2.8 M |
Additional Tools for VTv Stock Analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.